University of Bari   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Bari Italy (1925)

Organization Overview

First Clinical Trial
1998
NCT00289263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Alfredo Di Leo | Antonio Di Mauro | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Italy | Azienda Ospedaliero-Universitaria Policlinico Consorziale - Bari | Azienda Sanitaria Locale Bari | Bari University | Clinica Medica "A. Murri", DIMO - University of Bari | Clinica Neurologica I Policinico di Bari, Italy | Department of Biomedical Sciences and Human Oncology - Clinica Medica "A. Murri" | Department of Emergency and Organ Transplant, Division of Cardiac Surgery. University of Bari, Italy | Oncology Institute, Bari, Italy | Oncology Institute of Bari | University of Bari | University of Bari Aldo Moro | University of Bari, Italy

Active Ingredients

Drugs in Phase 4 Trials (19)

anacaulase (NexoBrid) (2 trials)

antithrombin iii (human) (thrombate iii) (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium infantis (1 trial)

bifidobacterium longum (2 trials)

boswellia serrata (1 trial)

centella asiatica (1 trial)

desmopressin (ddavp) (1 trial)

gynatren (1 trial)

lactobacillus plantarum (1 trial)

lactobacillus reuteri (7 trials)

multivitamins (1 trial)

nystatin (mycostatin) (1 trial)

polyethylene glycol (1 trial)

simethicone (1 trial)

sodium chloride (2 trials)

starch (1 trial)

Streptococcus thermophilus (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 3 Trials (22)

amoxicillin (1 trial)

bevacizumab (avastin) (1 trial)

Bismuth Subcitrate Potassium (Pylera) (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

lactobacillus rhamnosus (2 trials)

levofloxacin (levaquin) (1 trial)

methylprednisolone (medrol) (1 trial)

metronidazole (flagyl) (1 trial)

paclitaxel (taxol) (2 trials)

pantoprazole (protonix) (1 trial)

pemetrexed (alimta) (1 trial)

pyridoxine (1 trial)

ribavirin (virazole) (1 trial)

rifabutin (mycobutin) (1 trial)

rituximab (rituxan) (1 trial)

safinamide (xadago) (1 trial)

tetracycline (tetrex) (1 trial)

urofollitropin (metrodin) (1 trial)

Drugs in Phase 2 Trials (5)

colchicine (colbenemid) (1 trial)

deferiprone (ferriprox) (1 trial)

levocarnitine (carnitor) (1 trial)

mitomycin (mutamycin) (1 trial)

Silibinin (1 trial)

Drugs in Other Trials (14)

arginine (1 trial)

beta-glucans (1 trial)

b multivitamins (1 trial)

dark chocolate (1 trial)

gluten (1 trial)

hydrolyzed collagen (1 trial)

lactobacillus delbrueckii (1 trial)

l. paracasei fermented milk (1 trial)

lysine (1 trial)

methylsulfonylmethane (1 trial)

olive oil (1 trial)

ubiquinol (1 trial)

vitamin c (1 trial)

vitamin e (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 2)

Aortic Valve Insufficiency (Phase 4)

Aortic Valve Stenosis (Phase 4)

Azoospermia (Phase 3)

Breast Neoplasms (Phase 3)

Candidiasis (Phase 4)

Colic (Phase 4)

Communicable Diseases (Phase 4)

Constriction, Pathologic (Phase 4)

Critical Illness (Phase 4)

Diabetes Insipidus (Phase 4)

Glomerulonephritis (Phase 3)

Glomerulonephritis, Membranous (Phase 3)

Helicobacter Infections (Phase 3)

Hemoglobinopathies (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis, Chronic (Phase 3)

Infections (Phase 4)

Insulin Resistance (Phase 2)

Iron Overload (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Kidney Failure, Chronic (Phase 2)

Laryngopharyngeal Reflux (Phase 4)

Lung Neoplasms (Phase 3)

Mitral Valve Insufficiency (Phase 4)

Mitral Valve Stenosis (Phase 4)

Motor Neuron Disease (Phase 2)

Parkinson Disease (Phase 3)

Premature Birth (Phase 1)

Recurrence (Phase 2)

Renal Insufficiency (Phase 4)

Respiratory Tract Infections (Phase 4)

Sclerosis (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial APIs: 60